Adaptive Biotechnologies, a Seattle, WA-based developer of next generation sequencing (NGS) of T-cell and B-cell receptors in the immune system, completed a $195m Series F financing round.
The round was led by Matrix Capital Management with participation from new investors Senator Investment Group, Tiger Management, Rock Springs Capital and an additional large healthcare investor, alongside participation from existing investors Viking Global, Casdin Capital and Alexandria Real Estate Equities.
The company, which is also backed by strategic investors Illumina, Celgene, BD Biosciences and LabCorp., intends to use the funds to support the commercialization of a novel target identification technology for T-cell therapy, and expedite global regulatory submissions, launch timelines for its products, and grow its database of adaptive immune receptors to inform future diagnostic and therapeutic discoveries across disease states.
Led by Chad Robins, President, CEO and Co-founder, Adaptive Biotechnologies combines high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors for laboratories around the world to execute research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics to improve patient care.
The financing follows the acquisition of Sequenta Inc. earlier in 2015 (read here).